Fluticasone furoate/vilanterol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Fluticasone furoate/vilanterol
Fluticasone furoate and vilanterol.svg
Combination of
Fluticasone furoate Corticosteroid
Vilanterol Ultra-long-acting β2 agonist
Clinical data
Trade names Breo Ellipta, Relvar Ellipta
AHFS/Drugs.com breo-ellipta
  • US: C (Risk not ruled out)
Routes of
Inhalation (DPI)
Legal status
Legal status
ATC code R03AK10 (WHO)

Fluticasone furoate/vilanterol (trade names Breo Ellipta and Relvar Ellipta) is a combination drug for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. It contains fluticasone furoate, an inhaled corticosteroid, and vilanterol, an ultra-long-acting β2 agonist (ultra-LABA).

In 2013, the drug was approved for use in the United States by the Food and Drug Administration for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema,[1] and the European Medicines Agency approved it as a second-line therapy for the treatment of COPD and asthma.[2]

There are; however, concerns that LABAs such as vilanterol increase the risk of deaths due to asthma.[1]


External links[edit]